RU2011101536A - Усовершенствованные пептидные медиаторы оттока холестерина - Google Patents

Усовершенствованные пептидные медиаторы оттока холестерина Download PDF

Info

Publication number
RU2011101536A
RU2011101536A RU2011101536/15A RU2011101536A RU2011101536A RU 2011101536 A RU2011101536 A RU 2011101536A RU 2011101536/15 A RU2011101536/15 A RU 2011101536/15A RU 2011101536 A RU2011101536 A RU 2011101536A RU 2011101536 A RU2011101536 A RU 2011101536A
Authority
RU
Russia
Prior art keywords
polypeptide
group
polypeptide according
mammal
peptidomimetic
Prior art date
Application number
RU2011101536/15A
Other languages
English (en)
Russian (ru)
Inventor
Джон К. БИЛИКИ (US)
Джон К. БИЛИКИ
Ян ЙОХАНССОН (US)
Ян Йоханссон
Original Assignee
Дзе Риджентс Оф Дзе Юниверсити Оф Калифорниа (Us)
Дзе Риджентс Оф Дзе Юниверсити Оф Калифорниа
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дзе Риджентс Оф Дзе Юниверсити Оф Калифорниа (Us), Дзе Риджентс Оф Дзе Юниверсити Оф Калифорниа filed Critical Дзе Риджентс Оф Дзе Юниверсити Оф Калифорниа (Us)
Publication of RU2011101536A publication Critical patent/RU2011101536A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2011101536/15A 2008-06-18 2009-06-17 Усовершенствованные пептидные медиаторы оттока холестерина RU2011101536A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7370808P 2008-06-18 2008-06-18
US61/073,708 2008-06-18

Publications (1)

Publication Number Publication Date
RU2011101536A true RU2011101536A (ru) 2012-07-27

Family

ID=41434685

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2011101536/15A RU2011101536A (ru) 2008-06-18 2009-06-17 Усовершенствованные пептидные медиаторы оттока холестерина

Country Status (14)

Country Link
US (1) US8415293B2 (enExample)
EP (1) EP2300038A4 (enExample)
JP (1) JP2011525181A (enExample)
KR (1) KR20110043597A (enExample)
CN (1) CN102123722A (enExample)
AU (1) AU2009260024A1 (enExample)
BR (1) BRPI0915422A2 (enExample)
CA (1) CA2727465A1 (enExample)
CL (1) CL2010001445A1 (enExample)
IL (1) IL209868A0 (enExample)
MX (1) MX2010014003A (enExample)
PE (1) PE20110106A1 (enExample)
RU (1) RU2011101536A (enExample)
WO (1) WO2009155366A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011139819A2 (en) * 2010-04-28 2011-11-10 The Regents Of The University Of California Creation of oxidation-resistant hdl mimetic peptides
CN105050614B (zh) * 2013-03-15 2019-04-05 加利福尼亚大学董事会 刺激胆固醇流出的具有降低的毒性的肽
MX2016014306A (es) 2014-05-02 2017-06-12 Cerenis Therapeutics Holding Sa Marcadores para terapia con lipoproteinas de alta densidad (hdl).
US11091529B2 (en) 2014-09-17 2021-08-17 The Regents Of The University Of California Peptides having reduced toxicity that stimulate cholesterol efflux
DK3319980T3 (da) * 2015-07-10 2021-11-22 Peptinovo Biopharma Inc Formuleringer til forbedring af virkningen af hydrofobe lægemidler
EP3464613A4 (en) 2016-05-31 2020-01-08 Institut de Cardiologie de Montréal CO-CULTURE SYSTEM AND METHOD FOR IN-VITRO EVALUATION OF CHOLESTERIN RETURN
CN110294791B (zh) * 2019-06-13 2023-02-21 倪京满 具有胆固醇外流活性的抗动脉粥样硬化肽类似物及其应用
CN111848742B (zh) * 2020-07-23 2021-03-23 南京医科大学 一种多肽及其制药用途
CN112511569B (zh) * 2021-02-07 2021-05-11 杭州筋斗腾云科技有限公司 网络资源访问请求的处理方法、系统及计算机设备
CN115300609A (zh) * 2021-05-08 2022-11-08 西湖大学 缺氧诱导脂滴相关蛋白(hilpda)在预防或治疗高血脂相关疾病中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7691965B2 (en) * 2002-05-08 2010-04-06 The Regents Of The University Of California Helical synthetic peptides that stimulate cellular cholesterol efflux
CA2672131C (en) 2006-12-13 2016-06-07 The Regents Of The University Of California Potent and selective mediators of cholesterol efflux

Also Published As

Publication number Publication date
CL2010001445A1 (es) 2012-03-16
CA2727465A1 (en) 2009-12-23
AU2009260024A1 (en) 2009-12-23
WO2009155366A3 (en) 2010-04-22
CN102123722A (zh) 2011-07-13
BRPI0915422A2 (pt) 2017-06-27
JP2011525181A (ja) 2011-09-15
US8415293B2 (en) 2013-04-09
PE20110106A1 (es) 2011-03-02
IL209868A0 (en) 2011-02-28
KR20110043597A (ko) 2011-04-27
MX2010014003A (es) 2011-02-15
EP2300038A2 (en) 2011-03-30
EP2300038A4 (en) 2013-09-04
US20110190196A1 (en) 2011-08-04
WO2009155366A2 (en) 2009-12-23

Similar Documents

Publication Publication Date Title
RU2011101536A (ru) Усовершенствованные пептидные медиаторы оттока холестерина
JP2922281B2 (ja) 環状抗凝集性ペプチド類
JP2004506693A5 (enExample)
JP2004536077A5 (enExample)
RU2006107605A (ru) Пептид (варианты), пара аминокислот, снижающие интенсивность по меньшей мере одного симптома воспалительного состояния, фармацевтическая композиция (варианты), лекарственное средство и фармацевтический набор на их основе
CA2489227A1 (en) Hla-a24-restricted cancer antigen peptides
JPH05506252A (ja) 改良トロンビン阻害剤
CA2758264A1 (en) Neuromedin u derivative
DK165988B (da) Modificerede egliner b og c, deres anvendelse som proteaseinhibitorer, fremgangsmaade til fremstilling deraf samt farmaceutiske praeparater indeholdende de modificerede egliner b og c
EA012440B1 (ru) Пептид, композиция на его основе для лечения патологий, связанных c воспалительными процессами
US11667675B2 (en) MASP inhibitory compounds and uses thereof
WO2012014214A2 (en) Peptides derived from plasminogen activator inhibitor-1 (pai-1) for the treatment of hypertension
JP2011525181A5 (enExample)
JP2010513311A5 (enExample)
Agerberth et al. Isolation and characterization of a 60-residue intestinal peptide structurally related to the pancreatic secretory type of trypsin inhibitor: influence on insulin secretion.
CN101372512B (zh) 一类抗凝血多肽及其用途
JPWO1997015598A1 (ja) 新規ペプチド
Poulter et al. Levitide, a neurohormone-like peptide from the skin of Xenopus laevis. Peptide and peptide precursor cDNA sequences.
CN106222155A (zh) 一种多肽及其在制备结肠炎及结肠炎相关结直肠癌药物中的应用
WO2008050133A2 (en) Inhibition of beta-amyloid aggregation
US7074892B2 (en) Thrombin generation inhibitors
JPH02262595A (ja) ポリペプチド誘導体
JP2015160827A (ja) 急性腎障害に起因する多臓器不全の予防又は治療薬
FI120501B (fi) p53-proteiinin pitoisuuksia säätelevien kalpaiinin aktiivisuuden inhibiittorien käyttö syöpälääkkeiden valmistuksessa
WO2011060018A2 (en) Compositions and methods for using peptides, modified peptides, peptidomimetics and fibrin derivatives

Legal Events

Date Code Title Description
FA93 Acknowledgement of application withdrawn (no request for examination)

Effective date: 20120618